- - -









- - -
Investment opportunities

Tips from an insider: Five innovative tech startups

Tips from an insider: Stockholm tech start-ups

5 hot life science firms in Stockholm

Stockholm's top five infrastructure projects

Four Stockholm-based ICT firms to watch

Stockholm pioneers life science research

ICT startups offer investment opportunity

Swedish companies ready for exit

Five med-tech investment opportunities

Six cleantech investment opportunities

- - -
Rankings and surveys

Sweden tops English-language skills ranking

Sweden ranked world's best country to grow old

Swedish passport world's best for travellers

Sweden second best country for mothers

Stockholm climbs in competitiveness rankings

Sweden among best countries to be born

Fortune: 'Stockholm top place for startups'

Sweden tops first global Web Index

Sweden world's second most innovative country

Stockholm world's 6th 'best city'

'Cool Stockholm' most competitive Nordic capital

Sweden has (second) best reputation in the world

Sweden among top in Internet download speed

Sweden scores highest in 'Rule of law index'

Stockholm world's No1 in intellectual capital

Sweden the world's most ICT-competitive country

Sweden great place for moms – but Norway better

Swedes place 4th in English skills ranking

Sweden among top ICT countries

Sweden’s 10 greenest brands

‘Sweden needs to sell itself more’

Sweden overtakes the US in competitiveness

Sweden 10th ‘most admired country globally’

Sweden climbs in 'doing business' ranking

Sweden among world's least corrupt nations

Sweden's mortality rates world's second lowest

Sweden a good place to die – but Britain is best

Children in Sweden have best lives

Sweden the most competitive EU nation

Safe to do business with Swedes

How Sweden became an innovation frontrunner

Nordic countries world's most food-secure

Sweden the world’s best country – politically

Swedish firms among world's top brands

Swedish brands climb in global ranking

Sweden tops government ranking - while US lags 

'Swedish model' outranks 'American dream'  

Sweden among world's least corrupt nations

The Swedish Wire is a media production company that provides high-quality text, image and video content for international clients.


Press release published at The Swedish Wire

AstraZeneca and Medicines for Malaria Venture (MMV) today announced a collaborative agreement designed to identify novel candidate drugs for the treatment of malaria. The agreement will initially allow MMV access to AstraZeneca's extensive compound library.  MMV will seek to identify promising compounds with the potential to treat malaria, including drug resistant strains of the disease. AstraZeneca CEO David Brennan announced the collaboration at the Fortune/TIME/CNN Global Forum in Cape Town, South Africa. 

Globally, malaria caused an estimated 863,000 deaths in 2008, mainly amongst vulnerable populations in the developing world. Today's malaria drugs require courses of treatment lasting days or even weeks and follow-up can be difficult in many malaria-endemic countries.  In some cases the disease has begun to develop resistance to existing drugs - a problem exacerbated, in part, by failure to complete courses of treatment.  MMV works to discover, develop and deliver new, effective and affordable anti-malarial drugs with simpler dosing regimens thereby encouraging patient compliance and helping reduce the risk of resistance developing. The ultimate goal is to find a one-dose cure for malaria. 

Under the terms of the agreement, scientists working with MMV will screen 500,000 compounds in AstraZeneca's unique library for activity against P. falciparum, the most lethal of malaria parasites. Prof. V. Avery at the Eskitis Institute for Cell and Molecular Therapies at Griffith University in Brisbane, Australia will conduct the screening on behalf of MMV. Promising compounds identified through the screening process will be starting points for antimalarial drug discovery projects. These compounds will be progressed through a discovery cascade at AstraZeneca's R&D facility in Bangalore, India, with the aim of identifying suitable candidates for clinical testing. 

David Brennan, AstraZeneca's CEO said: "Our experience with infection research, and indeed with all of our R&D efforts, has taught us that we will only find solutions to today's global health challenges through collaborative efforts. Opening up our compound library to MMV is an important step toward addressing the enormous unmet medical needs of the developing world. AstraZeneca is committed to being part of the solution and we look forward to working with MMV and all those with a stake in global health." 

Tim Wells, MMV's Chief Scientific Officer said:   "AstraZeneca has had a long standing interest in neglected disease, and we are delighted to be able to collaborate with the centre in Bangalore on this exciting project in malaria. The screening of their library will give us some new unique starting points.  However, the additional advantage is the Indian perspective: India has millions of cases of malaria per year, and in addition has a balance between Plasmodium falciparum and Plasmodium vivax.  Understanding and eliminating Indian malaria is one of the keys to eliminating malaria worldwide."

- ENDS - 


About MMV
Medicines for Malaria Venture, a not-for-profit public-private partnership, was established as a foundation in Switzerland in1999. It is dedicated to the reduction of the malaria burden in disease-endemic countries with the discovery, development and delivery of new, effective and affordable antimalarial drugs. Our vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease. 

MMV is currently managing the largest portfolio of antimalarial R&D projects ever assembled; almost 60 antimalarial projects in partnership with over 130 pharmaceutical, academic, and endemic-country partners in 44 countries. In 2009, in collaboration with partners, MMV launched its first ever product - a sweet-tasting, paediatric formulation, Coartem® Dispersible. Two other MMV-supported artemisinin combination therapies, Eurartesim? and Pyramax®, have been submitted to the EMA for regulatory approval. Seven further potential medicines are in clinical development. For more information please visit: www.mmv.org (http://www.mmv.org) 

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.  For more information please visit: www.astrazeneca.com (http://www.astrazeneca.com) 



Media Enquiries:
Neil McCrae               +44 20 7304 5045  (24 hours)          
Chris Sampson          +44 20 7304 5130  (24 hours)
Sarah Lindgreen         +44 20 7304 5033  (24 hours)           
Abigail Baron             +44 20 7304 5034  (24 hours) 

Investor Enquiries:
Karl Hård                  +44 207 304 5322      mob: +44 7789 654364 

MMV Contact: 

Jaya Banerji               +41 79 707 71 81        banerjij@mmv.org (banerjij@mmv.org)

This information was distributed by Cision

Latest Jobs for English speakers in Sweden


Jobs for English speakers in Sweden

Most Read Searched